Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

Nature medicine·2026
Same author

Clinical outcomes after transition from weight-based to fixed-dose glucarpidase for high-dose methotrexate toxicity at a large academic medical center.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Clinical characteristics and outcomes of adult IDH-mutant brainstem gliomas: Institutional case series and systematic review.

Neuro-oncology advances·2026
Same author

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Jun 8, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Recurrent high-grade glioma.

Eudocia C Quant1, Jan Drappatz, Patrick Y Wen

  • 1Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, SW430B, 44 Binney Street, Boston, MA, 02115, USA, equant@partners.org.

Current Treatment Options in Neurology
|September 16, 2010
PubMed
Summary

Treatment for recurrent high-grade glioma is debated. Clinical trials are optimal, but bevacizumab or bevacizumab with irinotecan are options if trials are unavailable. Personalized factors influence choices.

More Related Videos

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Related Experiment Videos

Last Updated: Jun 8, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Area of Science:

  • Neuro-oncology
  • Radiation Oncology
  • Medical Oncology

Background:

  • Recurrent high-grade glioma (HGG) presents complex treatment challenges with varied opinions on optimal strategies.
  • Bevacizumab has gained attention for recurrent glioblastoma following FDA approval, but its universal adoption is debated.
  • Accurate diagnosis distinguishing tumor progression from treatment effects like pseudoprogression is critical for guiding therapy.

Purpose of the Study:

  • To review current treatment options for recurrent high-grade glioma, considering patient-specific factors and emerging therapies.
  • To provide guidance on selecting appropriate therapies for patients with recurrent gliomas, particularly after standard treatments fail.

Main Methods:

  • Review of existing literature and clinical opinions on the management of recurrent high-grade glioma.
  • Consideration of prognostic factors including age, performance status, tumor histology, molecular markers (MGMT, 1p/19q), and prior treatments.
  • Evaluation of evidence for various treatment modalities: chemotherapy, targeted therapy, radiation, surgery, and investigational approaches.

Main Results:

  • Clinical trial enrollment is recommended as the primary option for most patients with recurrent HGG post-radiotherapy and temozolomide.
  • For patients unable to access trials, bevacizumab monotherapy or combination with irinotecan is a suggested alternative.
  • Specific recommendations are provided for anaplastic gliomas, including re-irradiation and chemotherapy options (temozolomide, PCV) based on histology and prior treatment.

Conclusions:

  • Treatment decisions for recurrent high-grade glioma require a personalized approach, integrating patient factors, tumor characteristics, and available therapeutic options.
  • While bevacizumab is a viable option, its role and optimal use in combination with other agents require careful consideration.
  • Further investigation into novel therapies, including targeted agents and immunotherapies, is ongoing and holds promise for future HGG management.